Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    JTE-451 | psoriasis

Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis (IMPACT-PS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03832738
Recruitment Status : Active, not recruiting
First Posted : February 6, 2019
Last Update Posted : November 6, 2019
Sponsor:
Information provided by (Responsible Party):
Akros Pharma Inc.

Brief Summary:
Study to evaluate the efficacy and safety of JTE-451 administered for 16 weeks in subjects with moderate to severe plaque psoriasis.

Condition or disease Intervention/treatment Phase
Plaque Psoriasis Psoriasis Skin Diseases Drug: JTE-451 Tablets Drug: Placebo Tablets Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double-blind
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of JTE-451 Administered for 16 Weeks in Subjects With Moderate to Severe Plaque Psoriasis (IMPACT-PS)
Actual Study Start Date : January 17, 2019
Estimated Primary Completion Date : May 2020
Estimated Study Completion Date : July 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: JTE-451 Dose 1
JTE-451 Tablets Dose 1 daily for 16 weeks.
Drug: JTE-451 Tablets
Active drug tablets containing JTE-451

Experimental: JTE-451 Dose 2
JTE-451 Tablets Dose 2 daily for 16 weeks.
Drug: JTE-451 Tablets
Active drug tablets containing JTE-451

Placebo Comparator: Placebo
Placebo Tablets daily for 16 weeks.
Drug: Placebo Tablets
Placebo tablets matching in appearance to the active drug tablets




Primary Outcome Measures :
  1. Proportion of subjects achieving a minimum 75% improvement from baseline in the psoriasis area and severity index (PASI-75) at Week 16 [ Time Frame: Week 16 ]

Secondary Outcome Measures :
  1. Proportion of subjects achieving PASI-50/PASI-75/PASI-90 [ Time Frame: Weeks 2, 4, 8, 12, 16 and 20 ]
  2. Change from baseline in Static Physician's Global Assessment (sPGA) score, used to determine the severity of subject's psoriatic lesion at a given time point using the following score: 0 (cleared), 1 (minimal), 2 (mild), 3 (moderate) and 4 (severe). [ Time Frame: Weeks 2, 4, 8, 12, 16 and 20 ]
  3. Number of adverse events [ Time Frame: 20 Weeks ]
  4. JTE-451 trough plasma concentrations [ Time Frame: Weeks 2, 4, 8, 12 and 16 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have had a history of moderate to severe plaque psoriasis for at least 6 months prior to Visit 1;
  • Subjects with moderate to severe plaque psoriasis covering ≥10% body surface area (BSA), with a psoriasis area and severity index (PASI) ≥12 and static Physician's Global Assessment (sPGA) score ≥3 at Visit 1 and Visit 2

Exclusion Criteria:

  • History of discontinuation of biologic therapies (including marketed and investigational drugs) directly targeting Interleukin (IL)-17A, IL-17A/F, IL-17 receptor A, IL-12/IL-23p40 or IL-23p19 due to lack of efficacy, according to the Investigator's judgment;
  • Prior exposure to retinoid-related orphan receptor (ROR)-γ inhibitors;
  • Presence of erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis or other skin conditions (e.g., clinically-significant eczema or severe acne) at Visit 1;
  • History or presence of itch due to underlying conditions other than plaque psoriasis which cause or influence pruritus of the skin within 12 months prior to Visit 1.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03832738


  Show 33 Study Locations
Sponsors and Collaborators
Akros Pharma Inc.

Layout table for additonal information
Responsible Party: Akros Pharma Inc.
ClinicalTrials.gov Identifier: NCT03832738     History of Changes
Other Study ID Numbers: AE451-G-18-004
First Posted: February 6, 2019    Key Record Dates
Last Update Posted: November 6, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Akros Pharma Inc.:
JTE-451
Psoriasis
Plaque psoriasis
IMPACT-PS
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases
Skin Diseases, Papulosquamous